Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain

Journal of Nuclear Medicine

Volumn 55, Issue 9, 2014, Pages 1513-1518

  Kehler, Jan ^a   Kilburn, John Paul ^a   Estrada, Sergio ^b   Christensen, Søren Rahn ^a   Wall, Anders ^c   Thibblin, Alf ^b   Lubberink, Mark ^c   Bundgaard, Christoffer ^a   Brennum, Lise Tøttrup ^a   Steiniger Brach, Björn ^a   Christoffersen, Claus Tornby ^a   Timmermann, Stine ^a   Kreilgaard, Mads ^d   Antoni, Gunnar ^b   Bang Andersen, Benny ^a,d   Nielsen, Jacob ^a  

^a H LUNDBECK A S   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

11C; 3H; Brain imaging; Lu AE92686; PDE10A; PET

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 5,8 DIMETHYL 2 [2 [(1 METHYL) 4 PHENYL 1H IMIDAZOL 2 YL] ETHYL] [1,2,4]TRIAZOLO[1,5 A]PYRIDINE C 11; 5,8 DIMETHYL 2 [2 [(1 METHYL) 4 PHENYL 1H IMIDAZOL 2 YL] ETHYL] [1,2,4]TRIAZOLO[1,5 A]PYRIDINE TRITIUM; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RADIOLIGAND; TRITIUM; UNCLASSIFIED DRUG; CARBON; CARBON 11; DIAGNOSTIC AGENT; LIGAND; PDE10A PROTEIN, HUMAN; PHOSPHODIESTERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CEREBELLUM; CORPUS STRIATUM; DOSE RESPONSE; DRUG BINDING; DRUG DEVELOPMENT; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MACACA FASCICULARIS; MALE; NEUROIMAGING; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; TITRIMETRY; ANIMAL; BRAIN; BRAIN IMAGING; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LU AE92686; PDE10A; PET; SPRAGUE DAWLEY RAT;

11C; 3H; BRAIN IMAGING; LU AE92686; PDE10A; PET;

ADULT; ANIMALS; BRAIN; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LIGANDS; MACACA FASCICULARIS; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84907007810     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.140178     Document Type: Article

References (24)

1. Menniti FS, Chappie TA, Humphrey JM, et al. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs. 2007;8:54-59.
2. Chappie T, Humphrey J, Menniti F, et al. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Devel. 2009;12:458-467.
3. Kehler J, Kilburn JP. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Pat. 2009;19:1715-1725.
4. Kehler J, Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des. 2011;17:137-150.
5. Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54:1205-1213.
6. Tu Z, Xu J, Jones LA, Li S, Mach RH. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol. 2010;37:509-516.
7. Funke U, Deuther-Conrad W, Schwan G, et al. Radiosynthesis and radiotracer properties of a7-(2-[18F]fluoroethoxy)-6-methoxypyrrolidinylquinazoline for imaging of phosphodiesterase 10A with PET. Pharmaceuticals (Basel). 2012;5:169-188.
8. Tu Z, Fan J, Li S, et al. Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem. 2011;19:1666-1673.
9. Celen S, Koole M, De AM, et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J NuclMed. 2010;51:1584-1591.
10. Andrés J-I, Angelis MD, Alcázar J, et al. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem. 2011;54:5820-5835.
11. Andres-Gil JI, Bormans GMR, De Angelis M, Celen S, inventors; Janssen Pharmaceutica N, assignee. Radiolabelled PDE10 ligands. WO2010097367. 2010.
12. Van Laere K, Ahmad RU, Hudyana H, et al. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging. 2013;40:254-261.
13. Van Laere K, Ahmad RU, Hudyana H, et al. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. J Nucl Med. 2013;54:1285-1293.
14. Zhang L, Villalobos A, Beck EM, et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J Med Chem. 2013;56:4568-4579.
15. Ritzen A, Kehler J, Langgaard M, et al., inventors; Lundbeck A/S, assignee. Novel phenylimidazole derivatives as PDE10A enzyme inhibitors for treating neurodegenerative disorder, psychiatric disorder, or drug addiction. WO2009152825. 2009.
16. Larsen AK, Brennum LT, Egebjerg J, et al. Selectivity of 3H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol. 2004;141:1015-1023.
17. Smith PK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85.
18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
19. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
20. Lammertsma AA, Bench CJ, Price GW, et al. Measurement of cerebral monoamineoxidase B activity using L-[11C]deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab. 1991;11:545-556.
21. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
22. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11 C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
23. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
24. Yaqub M, Boellaard R, van Berckel BN, et al. Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. Mol Imaging Biol. 2009;11:322-333.